Hillstream Biopharma Stock Net Asset
Hillstream Biopharma fundamentals help investors to digest information that contributes to Hillstream Biopharma's financial success or failures. It also enables traders to predict the movement of Hillstream Stock. The fundamental analysis module provides a way to measure Hillstream Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hillstream Biopharma stock.
Hillstream |
Hillstream Biopharma Company Net Asset Analysis
Hillstream Biopharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Hillstream Biopharma Net Asset | 6.69 M |
Most of Hillstream Biopharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hillstream Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Hillstream Biopharma has a Net Asset of 6.69 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Hillstream Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hillstream Biopharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hillstream Biopharma could also be used in its relative valuation, which is a method of valuing Hillstream Biopharma by comparing valuation metrics of similar companies.Hillstream Biopharma is currently under evaluation in net asset category among its peers.
Hillstream Fundamentals
| Return On Equity | -1.47 | |||
| Return On Asset | -0.78 | |||
| Current Valuation | 496.66 K | |||
| Shares Outstanding | 17.53 M | |||
| Shares Owned By Insiders | 38.90 % | |||
| Shares Owned By Institutions | 0.80 % | |||
| Number Of Shares Shorted | 52.74 K | |||
| Price To Book | 0.88 X | |||
| EBITDA | (6.88 M) | |||
| Net Income | (8.47 M) | |||
| Cash And Equivalents | 9.48 M | |||
| Cash Per Share | 0.82 X | |||
| Total Debt | 772.9 K | |||
| Current Ratio | 13.13 X | |||
| Book Value Per Share | 0.18 X | |||
| Cash Flow From Operations | (6.56 M) | |||
| Short Ratio | 0.20 X | |||
| Earnings Per Share | (0.76) X | |||
| Target Price | 4.0 | |||
| Market Capitalization | 4.23 M | |||
| Total Asset | 6.69 M | |||
| Retained Earnings | (15.38 M) | |||
| Working Capital | 5.54 M | |||
| Z Score | -2.34 | |||
| Net Asset | 6.69 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Hillstream Stock
If you are still planning to invest in Hillstream Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hillstream Biopharma's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |